Latest profit margin for Aerie Pharmaceuticals: -17.09% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2022
Trailing 12 months ending Sep 2022
Aerie Pharmaceuticals (AERI) currently reports a profit margin of -17.09% as of September 2022. That compares with -159.84% in the prior-year period — up 89.3% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Aerie Pharmaceuticals's profit margin history and peer comparisons.
Aerie Pharmaceuticals's profit margin increased from -159.84% to -17.09% — a 89.3% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Aerie Pharmaceuticals's profit margin of -17.09% is lower than the Healthcare sector average of 13.89%. That is roughly 223.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Aerie Pharmaceuticals's current -17.09% should be judged against Healthcare norms (sector average: 13.89%) and against AERI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -17.09%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Aerie Pharmaceuticals, and consider following AERI for alerts when major investors trade the stock.